BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 28879595)

  • 1. Preemptive plerixafor injection added to pegfilgrastim after chemotherapy in non-Hodgkin lymphoma patients mobilizing poorly.
    Partanen A; Valtola J; Ropponen A; Vasala K; Penttilä K; Ågren L; Pyörälä M; Nousiainen T; Selander T; Mäntymaa P; Pelkonen J; Varmavuo V; Jantunen E
    Ann Hematol; 2017 Nov; 96(11):1897-1906. PubMed ID: 28879595
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pre-emptive plerixafor injection increases blood neutrophil, lymphocyte and monocyte counts in addition to CD34+ counts in patients with non-Hodgkin lymphoma mobilizing poorly with chemotherapy plus G-CSF: potential implications for apheresis and graft composition.
    Varmavuo V; Mäntymaa P; Kuittinen T; Nousiainen T; Jantunen E
    Transfus Apher Sci; 2012 Jun; 46(3):257-62. PubMed ID: 22465758
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Blood graft composition after plerixafor injection in patients with NHL.
    Varmavuo V; Mäntymaa P; Nousiainen T; Valonen P; Kuittinen T; Jantunen E
    Eur J Haematol; 2012 Aug; 89(2):128-35. PubMed ID: 22536949
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blood graft lymphocyte subsets after plerixafor injection in non-Hodgkin's lymphoma patients mobilizing poorly with chemotherapy plus granulocyte-colony-stimulating factor.
    Varmavuo V; Mäntymaa P; Kuittinen T; Nousiainen T; Jantunen E
    Transfusion; 2012 Aug; 52(8):1785-91. PubMed ID: 22304442
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plerixafor plus pegfilgrastim is a safe, effective mobilization regimen for poor or adequate mobilizers of hematopoietic stem and progenitor cells: a phase I clinical trial.
    Herbert KE; Demosthenous L; Wiesner G; Link E; Westerman DA; Came N; Ritchie DS; Harrison S; Seymour JF; Prince HM
    Bone Marrow Transplant; 2014 Aug; 49(8):1056-62. PubMed ID: 24887382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase 2 pilot study of pegfilgrastim and filgrastim for mobilizing peripheral blood progenitor cells in patients with non-Hodgkin's lymphoma receiving chemotherapy.
    Russell N; Mesters R; Schubert J; Boogaerts M; Johnsen HE; Canizo CD; Baker N; Barker P; Skacel T; Schmitz N
    Haematologica; 2008 Mar; 93(3):405-12. PubMed ID: 18268285
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of pre-emptively used plerixafor in patients mobilizing poorly after chemomobilization: a single centre experience.
    Jantunen E; Kuittinen T; Mahlamäki E; Pyörälä M; Mäntymaa P; Nousiainen T
    Eur J Haematol; 2011 Apr; 86(4):299-304. PubMed ID: 21198864
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A prospective comparison of pegfilgrastim and lipegfilgrastim combined with chemotherapy in the mobilization of CD34
    Partanen A; Turunen A; Valtola J; Vasala K; Ågren L; Penttilä K; Pyörälä M; Kuittinen T; Mäntymaa P; Pelkonen J; Jantunen E; Varmavuo V
    J Clin Apher; 2020 Aug; 35(4):255-263. PubMed ID: 32311780
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single-dose pegylated-filgrastim versus daily filgrastim after high-dose chemotherapy and autologous stem cell transplantation for lymphoid malignancies: delayed platelets recovery?
    Tendas A; Cupelli L; Bruno A; Niscola P; De Angelis V; Datturi T; Cantoni F; De Meis I; Dentamaro T; de Fabritiis P
    Blood Transfus; 2012 Oct; 10(4):561-2. PubMed ID: 22395357
    [No Abstract]   [Full Text] [Related]  

  • 10. Results of a Prospective Randomized, Open-Label, Noninferiority Study of Tbo-Filgrastim (Granix) versus Filgrastim (Neupogen) in Combination with Plerixafor for Autologous Stem Cell Mobilization in Patients with Multiple Myeloma and Non-Hodgkin Lymphoma.
    Bhamidipati PK; Fiala MA; Grossman BJ; DiPersio JF; Stockerl-Goldstein K; Gao F; Uy GL; Westervelt P; Schroeder MA; Cashen AF; Abboud CN; Vij R
    Biol Blood Marrow Transplant; 2017 Dec; 23(12):2065-2069. PubMed ID: 28797783
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of single-dose pegfilgrastim after chemotherapy for the mobilization of autologous peripheral blood stem cells in patients with malignant lymphoma or multiple myeloma.
    Kroschinsky F; Hölig K; Platzbecker U; Poppe-Thiede K; Ordemann R; Blechschmidt M; Oelschlaegel U; Schaich M; Hänel M; Bornhäuser M; Ehninger G
    Transfusion; 2006 Aug; 46(8):1417-23. PubMed ID: 16934080
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of plerixafor use in the mobilization of blood grafts for autologous hematopoietic cell transplantation.
    Jantunen E; Turunen A; Varmavuo V; Partanen A
    Transfusion; 2024 Apr; 64(4):742-750. PubMed ID: 38407504
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plerixafor as first- and second-line strategies for autologous stem cell mobilization in patients with non-Hodgkin's lymphoma or multiple myeloma.
    Lor KW; Helmons PJ; Belew H; Lane JR; Ball ED
    Pharmacotherapy; 2012 Jul; 32(7):596-603. PubMed ID: 22760691
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pegfilgrastim- versus filgrastim-based autologous hematopoietic stem cell mobilization in the setting of preemptive use of plerixafor: efficacy and cost analysis.
    Costa LJ; Kramer C; Hogan KR; Butcher CD; Littleton AL; Shoptaw KB; Kang Y; Stuart RK
    Transfusion; 2012 Nov; 52(11):2375-81. PubMed ID: 22404694
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pegfilgrastim appears equivalent to daily dosing of filgrastim to treat neutropenia after autologous peripheral blood stem cell transplantation in patients with non-Hodgkin lymphoma.
    Rifkin R; Spitzer G; Orloff G; Mandanas R; McGaughey D; Zhan F; Boehm KA; Asmar L; Beveridge R
    Clin Lymphoma Myeloma Leuk; 2010 Jun; 10(3):186-91. PubMed ID: 20511163
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kinetics of blood CD34(+) cells after chemotherapy plus G-CSF in poor mobilizers: implications for pre-emptive plerixafor use.
    Jantunen E; Varmavuo V; Juutilainen A; Kuittinen T; Mahlamäki E; Mäntymaa P; Nousiainen T
    Ann Hematol; 2012 Jul; 91(7):1073-9. PubMed ID: 22302373
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mobilization characteristics, blood graft composition, and outcome in diffuse large B-cell lymphoma after autologous stem cell transplantation: Results from the prospective multicenter GOA study.
    Partanen A; Turunen A; Valtola J; Pyörälä M; Vasala K; Kuittinen O; Kuitunen H; Penttilä K; Keskinen L; Kuittinen T; Mäntymaa P; Pelkonen J; Varmavuo V; Jantunen E
    Transfusion; 2021 Feb; 61(2):516-525. PubMed ID: 33245582
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment with plerixafor in non-Hodgkin's lymphoma and multiple myeloma patients to increase the number of peripheral blood stem cells when given a mobilizing regimen of G-CSF: implications for the heavily pretreated patient.
    Stiff P; Micallef I; McCarthy P; Magalhaes-Silverman M; Weisdorf D; Territo M; Badel K; Calandra G
    Biol Blood Marrow Transplant; 2009 Feb; 15(2):249-56. PubMed ID: 19167685
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Growth factor plus preemptive ('just-in-time') plerixafor successfully mobilizes hematopoietic stem cells in multiple myeloma patients despite prior lenalidomide exposure.
    Costa LJ; Abbas J; Hogan KR; Kramer C; McDonald K; Butcher CD; Littleton A; Shoptaw K; Kang Y; Stuart RK
    Bone Marrow Transplant; 2012 Nov; 47(11):1403-8. PubMed ID: 22484324
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plerixafor: A chemokine receptor-4 antagonist for mobilization of hematopoietic stem cells for transplantation after high-dose chemotherapy for non-Hodgkin's lymphoma or multiple myeloma.
    Steinberg M; Silva M
    Clin Ther; 2010 May; 32(5):821-43. PubMed ID: 20685493
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.